ISSN : 1226-6396
Objectives: Delayed encephalopathy after acute carbon monoxide poisoning (DEACMP) is a neurological complication that can occur following a pseudo-recovery phase after acute carbon monoxide poisoning (ACMP). Current treatments, such as Hyperbaric Oxygen (HBO) therapy and various pharmacological agents for DEACMP, have shown limited effectiveness. Given the reported benefits of East Asian herbal medicine (EAHM) in managing cerebral ischemia through antioxidant, anti-inflammatory, and anti-apoptotic mechanisms, EAHM may offer therapeutic potential for DEACMP. However, no systematic reviews of the clinical reports on this topic have been conducted thus far. This review aims to analyze the efficacy and safety of EAHM in patients with DEACMP. Methods: We will search eleven electronic databases and review randomized controlled trials of EAHM in patients with DEACMP. Results: The primary outcomes will include scores from the Mini-Mental State Examination and the Montreal Cognitive Assessment. The Cochrane risk-of-bias tool will be used for quality assessment. A meta-analysis will be conducted to evaluate the efficacy and safety of EAHM in this patient population. Conclusions: This review will provide clinical evidence regarding the efficacy and safety of EAHM for patients with DEACMP. The findings will be beneficial for clinicians and researchers involved in the care of these patients and will inform the design of future clinical studies.
Carbon monoxide (CO) is a tasteless, odorless, and colorless gas that exerts its toxic effects by forming carboxyhemoglobin upon inhalation, leading to hypoxic-ischemic cellular injury1) . Globally, the cumulative incidence and mortality rate of CO poisoning are estimated to be 137 cases and 4.6 deaths per million population, respectively2). Historically, acute CO poisoning (ACMP) has been linked to improper use of heating devices and exposure to the gas. However, the incidence of ACMP cases resulting from suicide attempts has demonstrated an upward trend3,4). Internationally, the inhalation of gases accounts for 5∼15% of suicides, with CO being the most frequently inhaled gas5) .
CO exhibits a 200- to 250-fold greater affinity for hemoglobin than that noted with oxygen, thus interfering with the oxygen supply and inhibiting cytochrome oxidase in mitochondria, leading to tissue hypoxia6,7). In ACMP, the central nervous system sustains significant damage, with the risk of neurological sequelae, including cognitive dysfunction, psychiatric issues, vestibular dysfunction, and motor impairment, ranging from 10% to 30%8). The hippocampus, basal ganglia, and cerebral cortex, regions particularly susceptible to ischemia and oxidative stress, are among the areas primarily affected9,10). Delayed encephalopathy after acute carbon monoxide poisoning (DEACMP) is a neurological complication that occurs in 10∼20% of patients with ACMP following a pseudo-recovery period lasting from 10 to 40 days11). Moreover, DEACMP causes memory loss, behavioral and mood disorders, mild cognitive impairment, severe dementia, vision loss, psychosis, and extrapyramidal symptoms, all of which severely diminish quality of life12). The diagnosis of DEACMP involves a history of CO exposure, the presence of a lucid interval lasting approximately two days to two months (with an average duration of 22 days)13), and the identification of brain lesions through computed tomography or magnetic resonance imaging (MRI)14). The prognosis of DEACMP is generally poor and prolonged, with severe cases potentially being fatal8,15,16).
The mechanisms underlying DEACMP remain unclear, which is why symptomatic treatment is typically selected, with hyperbaric oxygen (HBO) therapy being the most common17,18). However, the efficacy of HBO for DEACMP in the chronic phase of CO exposure remains unclear, and adverse effects such as severe fatigue, memory loss, and reduced concentration have been reported following two or more HBO sessions18). In addition, pulmonary edema, seizures, and increased free radical production may occur during HBO therapy19). Pharmacological interventions for DEACMP include N-butylphthalide (NBP) and dexamethasone in combination with mesenchymal stem cell transplantation, HBO, oxiracetam injections, and others20-24). However, the evidence supporting these pharmacological treatments remains inconclusive, and existing randomized controlled trials (RCTs) are limited by various methodological constraints20-24). Additionally, NBP has been reported to cause adverse effects, including nausea, vomiting, liver function impairment, insomnia, dizziness, and fatigue25). Dexamethasone is associated with a spectrum of side effects, ranging from common symptoms, such as insomnia, gastrointestinal discomfort, fluid retention, mood changes, to serious complications, including adrenal suppression, cardiac arrhythmias, electrolyte disturbances, and increased intracranial pressure26).
Cerebral ischemia arises through multiple pathways; consequently, effective neuroprotective therapies must target the diverse underlying pathological mechanisms27). Unlike pharmacological treatments, East Asian herbal medicine (EAHM) is composed of diverse bioactive compounds and thus offers synergistic effects through various pathological mechanisms28). Preclinical studies have shown that EAHM monomers promote neurological recovery after cerebral ischemia–reperfusion injury by alleviating oxidative stress, inhibiting inflammation, preventing neuronal loss and dysfunction, and reducing the size of cerebral infarcts29). Furthermore, EAHM is utilized to manage stroke and exerts therapeutic effects via multiple mechanisms, including suppression of ischemia-induced inflammation, scavenging of free radicals, inhibition of neuronal apoptosis, and regulation of blood lipid levels30-32). Notably, the EAHM exerts multi-targeted effects on numerous apoptotic pathways, including modulation of the mitochondrial, death receptor, and endoplasmic reticulum-mediated apoptotic pathways33). Moreover, the EAHM has demonstrated efficacy and safety in patients with stroke when administered either as a monotherapy or in combination with conventional Western medicine34-36). In Korea, clinical practice guidelines have been developed that recommend EAHM for treating patients with stroke and vascular dementia37,38).
Despite the possibility of EAHM addressing DEACMP, only one meta-analysis indicated that Buyanghuanwu-tang (Boyanghwanoh-tang) may be effective for the condition. A recent review summarizes RCTs evaluating the use of EAHM in patients with DEACMP over the past eight years39,40). However, to date, no comprehensive systematic review has provided evidence regarding the use of EAHM in the treatment of patients with DEACMP. Therefore, this review will aim to analyze the efficacy and safety of EAHM in patients with DEACMP.
This systematic review will be conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement for meta-analyses41). This protocol will adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-P (PRISMA-P) guidelines for systematic review protocols (Supplementary 1)42). This protocol was registered with PROSPERO on April 8, 2025, and the registration number is CRD420251028249.
This review will include RCTs, pilot, and feasibility studies, as well as study designs, and exclude case reports, cross-sectional studies, reviews, and mechanistic or animal experimental studies. Academic theses, dissertations, and conference proceedings will also be excluded.
This review will include adults aged ≥18 years who were diagnosed with DEACMP. Studies that enrolled patients with CO poisoning diagnosed according to the corresponding clinical guideline criteria, MRI, or computed tomography will be included. Only studies that used certain diagnostic criteria for depression, such as the Diagnostic and Statistical Manual of Mental Disorders, International Classification of Diseases, Chinese Classification of Mental Disorders, Standard of Traditional Chinese Medicine Diagnosis and Treatment Effect, and Guiding Principles for Clinical Research on New Drugs of Traditional Chinese Medicine, will be included. Studies using clinical symptoms, including apathy, dementia, disorientation, ataxia, amnesia, psychiatric symptoms, extrapyramidal symptoms, pyramidal symptoms, tremors, paralysis, increased muscle tone, memory loss, and dullness, as diagnostic criteria will also be included, along with those using electroence-phalography (EEG), Mini-Mental State Examination, and Montreal Cognitive Assessment as diagnostic criteria. However, patients with pre-existing psychiatric illnesses before CO poisoning will be excluded. Studies that do not provide diagnostic criteria or utilize validated assessment tools will be excluded from this review. No restrictions will be placed on the participants’ sex or race.
This review will include studies using EAHM alone or in combination with routine care for DEACMP, including HBO, neurotrophic agents, cerebral cell activators, circulation enhancers, anticoagulants, and anti-inflammatory agents. Additionally, studies involving the use of other pharmacological treatments for comorbid conditions will be included. Furthermore, those utilizing EAHM in various forms, such as decoctions, injections, capsules, granules, and powders, will also be considered. Studies using EAHM combined with acupuncture-related therapies (acupuncture, acupressure, moxibustion), herbal bathing, and other treatments will be excluded.
The primary evaluation tools for evaluating changes in the severity of DEACMP will be the Mini-Mental State Examination and the Montreal Cognitive Assessment.
Secondary outcomes will be the total effective rate, changes observed in MRI, EEG, and blood biomarkers such as high-sensitivity C-reactive protein, interleukin-6, neuron-specific enolase, and S100 beta protein. In addition, safety will be evaluated based on reported adverse events.
Eleven electronic databases, including PubMed, Embase via Elsevier, the Cochrane Central Register of Controlled Trials, Web of Science, SCOPUS via Elsevier, Allied and Complementary Medicine Database via EBSCO, PsycARTICLES via ProQuest, Oriental Medicine Advanced Searching Integrated System, Korea Citation Index, China National Knowledge Infrastructure, and Citation Information by NII, were searched on July 5, 2025, by independent researchers(BJ Kim, EY Ju). Moreover, gray literature will be searched using Google Scholar, and the reference lists of the relevant systematic reviews and retrieved articles will be manually examined. The search strategy will employ a combination of synonyms and related Medical Subject Headings terms (Supplementary 2).
All studies retrieved using the search strategy will be imported into EndNote 20.6 (Clarivate Analytics, Boston, USA), and duplicated studies will be filtered. The titles and/or abstracts of the retrieved studies, as well as those from additional sources, will be screened by two independent researchers (BJ Kim and EY Ju) to identify studies that potentially meet the inclusion criteria outlined above. The full texts of these potentially eligible studies will be retrieved and independently assessed for eligibility by two researchers (BJ Kim and EY Ju). Any disagreements regarding the eligibility of specific studies will be resolved through discussion, and if a consensus cannot be reached, a third researcher (SH Kim) will make the final decision.
Two researchers (BJ Kim and EY Ju) will independently review and extract data from the selected studies. If no consensus can be reached, disagreements will be resolved through discussion. However, if a consensus cannot be reached, a third researcher (SH Kim) will make the final decision. We will employ a standardized data extraction form that will include the source, author, year of publication, study design, participant characteristics, concomitant diseases, intervention, comparator, duration, follow-up, outcome measurements, results, and adverse effects. Microsoft Excel 2013 (Microsoft Corporation, Washington, USA) will be used for the data and information management.
The risk of bias 2.0 Excel tool will be used to assess the quality of the studies by two independent researchers (BJ Kim, EY Ju), presented in the Cochrane Handbook for Systematic Reviews of Interventions(version 6.5), in Review Manager software version 5.4(RevMan 5.4) (Copenhagen, The Nordic Cochrane Centre, the Cochrane Collaboration, 2020)43). The following characteristics will be considered: 1) randomization process, 2) deviations from intended interventions, 3) missing outcome data, 4) outcome measurement, 5) selection of reported results, and 6) overall bias. The risk of bias will be graded as high, low, or some concerns. Disagreements will be resolved by a third researcher (SH Kim).
A narrative synthesis of the findings from the included studies will be provided. For instance, demographic characteristics of the participants and details of the experimental and control interventions, outcomes, and results will be presented. For dichotomous variables, RR was used; meanwhile, for continuous variables, MD or SMD with a 95% CI was employed. Due to the use of various scales for MRI, EEG, and blood biomarker measurements, which represent key outcome measures, the SMD will be employed. Given the heterogeneity in the demographic characteristics of the participants, severity of DEACMP, prescribed treatments, control groups, and treatment duration across the included studies, clinical heterogeneity will be considered significant. Therefore, regardless of the I2 value, a random-effects model will be used for post-hoc analysis. However, if the number of included studies is very small, a fixed-effects model will be used for post-hoc analysis. RevMan 5.4 will be used to summarize and synthesize the effects of studies employing the same intervention and control groups. If feasible, subgroup analyses will be conducted based on treatment duration, prescription type, or fistula classification within the EAHM intervention. Additionally, we will perform a sensitivity analysis by excluding (1) studies with a high risk of bias and (2) those whose CIs do not overlap with that of the pooled effect. Sensitivity analysis will be conducted by excluding studies with a high risk of bias and those with substantial heterogeneity, specifically when the CIs of the individual scales do not overlap with the overall CI of the meta-analysis.
Certainty of evidence from the included studies will be examined via the Grading of Recommendations, Assessment, Development and Evaluation44). The level of certainty will be categorized into high, moderate, low, and very low grades, based on the risk of bias, imprecision, indirectness, inconsistency, and publication bias. Factors that may minimize certainty include the risk of bias, imprecision, indirectness, inconsistency, and publication bias. Conversely, a large magnitude of effect, a dose-response gradient, and plausible confounding factors may increase the certainty of evidence.
DEACMP is characterized by neuronal apoptosis and necrosis, leading to irreversible damage to neural function through ischemia and hypoxia, oxidative stress injury, and reperfusion-oxygenation injury7,45,46). The pathogenesis of DEACMP remains poorly understood, with effective treatment options being limited47). Although HBO therapy is currently the first-line treatment for DEACMP, the efficacy of this modality remains inconclusive18). Several studies have reported inconsistent clinical outcomes of HBO in patients with DEACMP depending on the comorbidities, hypermyotonia, and HBO treatment pressure48,49). This has raised concerns about the potential adverse effects associated with HBO50).
Pharmacological interventions such as NBP, dexamethasone, and oxiracetam have been used to treat DEACMP, but they lack conclusive evidence of multi-target capability20-24). In contrast, EAHM, a multi-component preparation, has demonstrated neuroprotective, antioxidant, anti-inflammatory, and lipid-regulating effects across various neurological disorders35,51,52). The mechanisms through which individual East Asian herbs effectively treat cerebral ischemia have been identified53-57). Panax quinquefolius L. confers neuroprotection against ischemia–reperfusion injury through upregulating the activities of antioxidant enzymes such as catalase, superoxide dismutase, and glutathione53). Angelica gigas reduces the levels of oxidative stress and pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), increasing cerebral blood flow and promoting neuronal recovery54). Astragalus membranaceus suppresses oxidative stress and exhibits neuroprotective effects by activating the Nrf2 pathway and upregulating BDNF expression via the AKT/CREB signaling pathway55). Polygala tenuifolia protects neurons in the process of hypoxia/reoxygenation injury by anti-apototic and anti-oxidant effects56). Salvia miltiorrhiza exerts neuroprotective effect in cerebral ischemia-reperfusion injury by downregulating TLR4, p-p38MAPK, p-JNK, NF-κB, and IL-1β57). NBP and dexamethasone have been reported to have minor to cause adverse effects, ranging from mild to severe25,26). Conversely, the safety and efficacy of EAHM have been reported for the treatment of ischemic stroke36). Considering its traditional use in enhancing cognitive function and promoting recovery from brain injuries, the EAHM is expected to offer a viable complementary or alternative approach in the treatment of DEACMP58-60).
No comprehensive synthesis of evidence from RCTs has assessed the clinical efficacy and safety of herbal medicines for DEACMP. This systematic review and meta-analysis will be the first to evaluate the therapeutic potential of herbal medicine in the management of DEACMP by analyzing available RCTs. The findings of this study are expected to provide robust evidence for clinical decision making and contribute to the development of evidence-based guidelines. Furthermore, this review will offer critical insights for future research, including the identification of specific herbal formulae in the context of DEACMP.
SUPPLEMENTARY MATERIALS Supplementary materials can be found via https://doi.org/10.7231/jon.2025.36.3.217
, , (2023, cited 2025 Aug 6, May 2) StatPearls Treasure Island (FL): StatPearls Publishing Internet, updated 2023 May 2, Available from: https://www.ncbi.nlm.nih.gov/books/NBK482130/, Dexamethasone
Clinical Practice Guideline Development Project Group of Korean Medicine (2021) Clinical Practice Guideline for Stroke in Korean Medicine Gyeongsan (Korea): National Institute for Korean Medicine Development Available from: https://nikom.or.kr/nckm/module/practiceGuide/view.do?guide_idx=159
Clinical Practice Guideline Development Project Group of Korean Medicine (2021) Korean Medicine Clinical Practice Guideline for Dementia Gyeongsan (Korea): National Institute for Korean Medicine Development Available from: https://nikom.or.kr/nckm/module/practiceGuide/view.do?guide_idx=169&menu_idx=14
American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Carbon Monoxide Poisoning, , , , , (2017) Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with acute carbon monoxide poisoning Ann Emerg Med, 69(1), 98-107 .